Plan Name [Axis] 2015 Long-term Incentive Plan [Member] Income Statement Location [Axis] General and Administrative Expense [Member] Exercise Price Range [Axis] Exercise Price 0.11-0.55 [Member] Exercise Price 2.00-3.85 [Member] Range [Axis] Minimum [Member] Maximum [Member] Exercise Price 5.10-7.20 [Member] Exercise Price 0.11-7.20 [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Exclusive License Agreement [Member] Title of Individual [Axis] Dr. Brent Satterfield [Member] Antidilutive Securities [Axis] Outstanding Options [Member] Options [Member] Outstanding Warrants [Member] Warrants [Member] Long-term Debt, Type [Axis] Unsecured Debt [Member] CAD [Member] Nine Employees [Member] Three Independent Members [Member] Three Members Our Board of Directors [Member] Equity Components [Axis] Warrant [Member] Award Date [Axis] 2018 [Member] 2019 [Member] 2020 [Member] Legal Entity [Axis] DNA Logix-Canada [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Ex Transition Period Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS: Current Assets Cash and cash equivalents Other receivables Inventory Prepaid expenses Total current assets Other Assets Property and equipment, net Investment in joint venture Total other assets Total assets LIABILITIES AND STOCKHOLDERS' EQUITY: Current Liabilities Accounts payable Accrued expenses Accrued expenses (related party) Notes payable net of discount of $130,988 and $0 Deferred income-current Total current liabilities Long-term Liabilities, net of current portion Accrued expenses-long-term (related party) Deferred income-long-term Total long-term liabilities, net of current portion Total liabilities Commitments and contingencies STOCKHOLDERS' EQUITY : Common stock, $.001 par value, 180,000,000 shares authorized; 12,665,023 and 12,317,184 shares issued and outstanding, respectively. Additional paid-in capital Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Notes payable, discount Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Net sales Cost of sales Gross profit Operating expenses: Sales and marketing Administrative and general Research and development Depreciation and amortization Total operating expenses Loss from operations Other expense: Interest income Interest expense Loss on extinguishment of debt Loss on disposition of assets Gain on equity method investment in joint venture Total other expense Loss before income taxes Provision for income taxes Net loss Basic and diluted income (loss) per common share Weighted average common shares outstanding, basic and diluted Statement of Cash Flows [Abstract] Cash flows from operating activities: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Stock based compensation Accretion of notes payable discount Loss on extinguishment of debt Loss on disposition of assets Gain of equity method investment Changes in assets and liabilities: Increase (decrease) in deferred income Decrease in prepaid and other assets Increase (decrease) in accounts payable and accrued expenses Net cash used in operating activities Cash flows from investing activities: Purchase of property and equipment Investment in joint venture Net cash used by investing activities Cash flows from financing activities: Proceeds from the sale of equity Proceeds from the issuance of debt Payment of deferred debt acquisition costs Principal payments on debt (related party) Payment of deferred offering costs Net cash provided by financing activities Net increase (decrease) in cash Cash and cash equivalents beginning of period Cash and cash equivalents end of period Supplemental disclosure of cash flow information: Interest paid Schedule of non-cash investing and financing activities: Warrants issued for services Accounting Policies [Abstract] Basis of Presentation Significant Accounting Policies Debt Disclosure [Abstract] Notes Payable Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stock-based Compensation Related Party Transactions [Abstract] Related Party Transactions Insurance [Abstract] Lease Obligations Subsequent Events [Abstract] Subsequent Events Earnings (Loss) Per Share Use of Estimates Schedule of Fair Values Options Weighted Average Assumptions Summary of Option Activity Schedule of Fair Values Warrants Assumptions Summary of Warrant Activity Summary of Stock Option and Warrant Outstanding Schedule of Unrecognized Stock-based Compensation Schedule of Lease Rent Obligations Statement [Table] Statement [Line Items] Antidilutive securities potentially dilutive shares Debt principal amount Debt interest rate Debt maturity date Note repayable Interest expense Notes payable Aggregate number of common shares reserved Unissued common stock options authorized shares Number of options granted Options granted, value Weighted average fair value of options granted Stock-based compensation expense related to granted Options vesting amount Warrants issued Weighted average fair value, warrant issued Unrecognized stock-based compensation Stock issued for services Risk free interest rate Expected life (in years) Expected volatility Expected dividend yield Stock price Options Outstanding, Beginning Options Outstanding Options granted Options Outstanding Expired Options Outstanding Forfeited options Options Outstanding Exercised Options Outstanding Ending Weighted Average Exercise Price Outstanding, Beginning Weighted Average Exercise Price Options granted Weighted Average Exercise Price Expired Weighted Average Exercise Price Forfeited options Weighted Average Exercise Price Exercised Weighted Average Exercise Price Outstanding, Ending Weighted Average Fair Value Outstanding, Beginning Weighted Average Fair Value Options granted Weighted Average Fair Value Expired Weighted Average Fair Value Forfeited options Weighted Average Fair Value Exercised Weighted Average Fair Value Outstanding, Ending Weighted-average Remaining Contractual Life Outstanding, Beginning Weighted-average Remaining Contractual Life Options granted Weighted-average Remaining Contractual Life Outstanding, Ending Warrant Outstanding, Beginning Warrant Outstanding, Warrants issued Warrant Outstanding, Expired Warrant Outstanding, Forfeited warrants Warrant Outstanding, Exercised Warrant Outstanding, Ending Weighted Average Exercise Price, Beginning Weighted Average Exercise Price, Warrant issued Weighted Average Exercise Price, Expired Weighted Average Exercise Price, Forfeited warrants Weighted Average Exercise Price, Exercised Weighted Average Exercise Price, Ending Weighted Average Fair Value, Beginning Weighted Average Fair Value, Warrant issued Weighted Average Fair Value, Expired Weighted Average Fair Value, Forfeited warrants Weighted Average Fair Value, Exercised Weighted Average Fair Value, Ending Weighted-average Remaining Contractual Life (Years), Beginning Weighted-average Remaining Contractual Life (Years), Warrants issued Weighted-average Remaining Contractual Life (Years), Ending Exercise Prices Number outstanding Weighted average remaining contractual life Weighted average exercise price Number exercisable Weighted average exercise price exercisable Total Accrued royalties Royalty payments, per month Research and development expense Due to related party Area of land Contract lease per month Lease expiration date Rent expenses 2018 2019 2020 Total Payments for license fee Number of common stock issued Issuance of warrant to acquire common stock Exercise price of warrant Warrant expiration term Exclusive License Agreement [Member] 0.11-0.55 [Member] 2.00-3.85 [Member] 0.11-7.20 [Member] 5.10-7.20 [Member] Summary of Stock Option and Warrant Outstanding [Table Text Block] 2015 Long-term Incentive Plan [Member] Warrants issued for services. Payment of deferred offering costs. Options [Member] Warrants [Member] Note Purchase Agreement [Member] Promissory Note [Member] Outstanding Options [Member] Outstanding Warrants [Member] Schedule of Fair Values Warrants Assumptions [Table Text Block] Payment of deferred debt acquisition costs. CAD [Member] Employees [Member] Nine Employees [Member] Options granted, value. Three Independent Members [Member] Three Members Our Board of Directors [Member] Options vesting amount. The number of equity-based payment instruments, excluding stock (or unit) options, that were Expired during the reporting period. The number of equity-based payment instruments, excluding stock (or unit) options, that were Exercised during the reporting period. Weighted average grant-date fair value of non-vested other than options outstanding. Share based compensation arrangement by share based payment award equity instruments other than options weighted average grant, Share based compensation arrangement by share based payment award equity instruments other than options weighted average Expired. Share based compensation arrangement by share based payment award equity instruments other than options weighted average forfeited. Share based compensation arrangement by share based payment award equity instruments other than options weighted average exercised. Share based compensation arrangement by share based payment award equity instruments other than options expired weighted average grant date fair value. Share based compensation arrangement by share based payment award equity instruments other than options exercised weighted average grant date fair value. Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible. Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. 2018 [Member] 2019 [Member] 2020 [Member] DNA Logix-Canada [Member] Payments for license fee. Share based compensation arrangement by share based payment award equity instruments other than options exercised weighted average grant date fair value. Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Dr. Brent Satterfield [Member] Assets, Current Assets, Noncurrent Assets Liabilities, Current Liabilities, Noncurrent Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses Operating Income (Loss) Interest Expense, Other Other Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Gain (Loss) on Sale of Equity Investments Increase (Decrease) in Deferred Income Taxes Increase (Decrease) in Prepaid Expenses, Other Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Payments to Acquire Interest in Joint Venture Net Cash Provided by (Used in) Investing Activities Proceeds from Related Party Debt PaymentOfDeferredOfferingCosts Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price 0.11-7.20 [Member] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Operating Leases, Future Minimum Payments Due